Skip to main content
main-content

Sodium-glucose cotransporter 2 (SGLT2) inhibitors

medwireNews top story

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Heart and white pills

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

Featured podcast

EASD 2020: Editorial Board conference highlights

Sanjay Kalra, Lori Berard, John Wilding

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting (39:05). 

EASD 2020

EMPEROR-Reduced: Time for a change in the HF guidelines?

Miles Fisher

Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).

EASD 2020

DAPA-CKD trial: Renal benefits of SGLT2 inhibition in people with and without diabetes

Hiddo Heerspink

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).

EASD 2020

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes

Milton Packer

Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).

EASD 2020 News

Further VERTIS-CV analysis supports ertugliflozin renal benefits

Heart kidney and nerves

The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.

medwireNews top story

SGLT2 inhibition ‘could overcome diuretic resistance’

Man handing container with urine sample to a doctor

A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.

medwireNews top story

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

Flatline alert_heart monitor

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

medwireNews top story

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

Pills and water (symbolic image with model)

The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.

medwireNews top story

DAPA-CKD shows dapagliflozin benefits regardless of diabetes

Kidneys

The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.

medwireNews

10-12-2020 | Ertugliflozin | Highlight | News

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

10-08-2020 | SGLT2 inhibitors | News

More real-world evidence for SGLT2 inhibitor cardioprotection

Further real-world evidence demonstrates the positive cardiovascular effects of SGLT2 inhibitors in people with type 2 diabetes, in this case when compared against DPP-4 inhibitors.

10-07-2020 | Empagliflozin | News

Real-world data support empagliflozin renoprotective effect

Real-world data suggest that the SGLT2 inhibitor empagliflozin is associated with estimated glomerular filtration rate preservation, weight loss, and a reduced risk for major adverse kidney events when compared with other antihyperglycemics among people with type 2 diabetes.

At a glance

07-03-2019 | Semaglutide | At a glance | Article

A quick guide to the PIONEER trials

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

11-28-2018 | SGLT2 inhibitors | At a glance | Article

Real-world studies of SGLT2 inhibition and amputation risk

How many real-world studies have looked at amputation risk in users of SGLT2 inhibitors, and do the findings support or refute the effect found in CANVAS? medwireNews rounds up the research so far.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

09-12-2018 | SGLT2 inhibitors | Article

Comparative risk of genital infections associated with SGLT2 inhibitors: A real‐world retrospective cohort study

Dave CV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13531

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits